Image source: Getty Images.
Global spending on cancer medicines topped $107 billion last year, and is expected to reach $150 billion by 2020. Over the past decade our understanding of how different cancers evade the immune system has grown immeasurably. Accordingly, in the past ten years the number of potential cancer medicines in mid- to late-stage clinical studies has grown 63% to 586, involving a whopping 511 companies.